

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 69783

**Title:** Heart failure as an adverse effect of infliximab for Crohn's disease: A case report and review of literature

**Reviewer's code:** 05665395

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Director, Professor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Brazil

**Manuscript submission date:** 2021-07-11

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-07-11 22:27

**Reviewer performed review:** 2021-07-13 12:21

**Review time:** 1 Day and 13 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

#### **SPECIFIC COMMENTS TO AUTHORS**

The manuscript is well, concisely and coherently organized and presented.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 69783

**Title:** Heart failure as an adverse effect of infliximab for Crohn's disease: A case report and review of literature

**Reviewer's code:** 04088775

**Position:** Editorial Board

**Academic degree:** BMed, FRACP, PhD

**Professional title:** Doctor, Staff Physician

**Reviewer's Country/Territory:** Australia

**Author's Country/Territory:** Brazil

**Manuscript submission date:** 2021-07-11

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-07-15 12:09

**Reviewer performed review:** 2021-07-15 12:30

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

The authors report a case of a patient who develops new heart failure approximately 6 months after commencing infliximab for Crohn's disease treatment. It is a well presented case. This is a well recognized complication of anti-TNF therapy but important for clinicians to be cognizant of when commencing anti-TNF therapy and the report provides a good overview of the topic. I have the following suggestions: - for the resected specimen, can you please provide histological findings such as the presence of granulomas or chronic inflammation - did the patient have any prior echocardiograms? Is it considered that the patients heart failure was entirely due to anti-TNF therapy or due to underlying hypertensive cardiomyopathy that was worsened by anti-TNF therapy? - do the authors propose any specific changes that their case and assessment of literature should be considered at higher risk of heart failure and what screening would be suggested? Minor points: Treatment section, first sentence - Opted for infliximab suspension, and furosemide was introduced. Please revise the grammar of this sentence.